Trial Investigating the Absorption, Metabolism and Excretion After a Single Subcutaneous Dose of [3H]-Semaglutide in Healthy Male Subjects

Sponsor
Novo Nordisk A/S
Study ID
NCT02060266
Phase
PHASE1
Status
Completed

Conditions

  • Diabetes
  • Healthy

Eligibility Criteria

Sex
MALE
Age
45 Years - 64 Years
Healthy Volunteers
Accepted

Interventions

  • semaglutide — DRUG
    Subjects will receive a single dose subcutaneously (s.c., under the skin).

Study Details

This trial is conducted in Europe. The aim of the trial is to investigate the absorption, metabolism and excretion after a single subcutaneous dose of \[3H\]-semaglutide in healthy male subjects.

Key Dates

Start date
Feb 4, 2014
Status verified
Mar 2017
Primary completion
Apr 28, 2014
Completion
Apr 28, 2014

Study Design

Enrollment
7 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Semaglutide

Primary Outcome Measure

Concentration of the major metabolites of [3H]-semaglutide in plasma, urine, and faeces [ Time Frame: Up to 9 weeks following a single dose of 0.5 mg [3H]-semaglutide ]

Related Studies